Microba Life Sciences (ASX:MAP) posted 92% core testing revenue growth for FY26 and a A$7m cost-out that reshapes the FY27 break-even case.
16
Stocks in Spotlight
View all →-
Growth Stocks · Financials Powerhouse Ventures (ASX:PVL) Merchant Model Delivers 22x and 240% Deal Wins July 15, 2026 -
AI Stocks · International Stocks SK hynix (NSDQ:SKHY) Surges 27% as Investors Reprice Its 58% HBM Leadership July 15, 2026 -
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) Builds a Merchant Revenue Engine as CIO Fund Scales July 3, 2026
